Skip to main content
Premium Trial:

Request an Annual Quote

Lynx and Solexa Tie the Knot; First Gene-Analysis Product Planned for End of Year

NEW YORK, March 7 (GenomeWeb News) - UK-based Solexa and Lynx Therapeutics of Hayward, Calif., have completed their previously announced merger, the companies said today.


The combined company, which will be called Solexa, is incorporated in Delawareand will start trading today on the Nasdaq SmallCap Market under the symbol SLXA. The company's UKoperation has become a wholly owned subsidiary, the firms said.


Solexa said it plans to launch its first product, a gene-analysis platform based on sequencing-by-synthesis and micorarrays, by the end of the year. Initially, the company will focus on the research market.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.